Replies to post #142728 on Biotech Values

[mcbio]

I don’t impose such a restriction—Zebra’s Law, as originally posited (#msg-23784371) applies to a company’s lead program regardless of how many other programs are behind it in the pipeline.

Rindo is technically CLDX's lead program, not CDX-011, but I think 011 has more promise so point taken. I do think the promising results in TN/HG make it unlikely Zebra's Law will be at play here.